Crispr Therapeut - CRSP STOCK NEWS

CRISPR Therapeutics announced the first patient has been dosed in a Phase 1 clinical trial for VCTX210, a gene-edited, stem-cell therapy aimed at treating type 1 diabetes. Developed in partnership with ViaCyte, VCTX210 is designed to produce insulin while evading immune rejection. The trial will assess safety, tolerability, and immune evasion capabilities. If successful, VCTX210 could provide a transformative treatment option for diabetes patients without the need for immunosuppression.

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences in December 2021. The first event is the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:35 p.m. ET. The second is the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021, at 1:00 p.m. ET. Webcast access will be available on CRISPR's website, with replays archived for 14 days post-event. CRISPR is focused on developing transformative gene-based medicines using its CRISPR/Cas9 platform.

CRISPR Therapeutics (Nasdaq: CRSP) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. This designation highlights the promising clinical data and aims to expedite drug development and review processes. CTX110 is being evaluated in the CARBON trial for safety and efficacy. The RMAT designation facilitates discussions with the FDA and potential accelerated approval, emphasizing the transformative potential of CTX110 for patients with hematological malignancies.

CRISPR Therapeutics and ViaCyte have received approval from Health Canada for their Clinical Trial Application (CTA) for VCTX210, a gene-edited therapy aimed at treating type 1 diabetes (T1D). This therapy promises to be immune-evasive and stem cell-derived. Patient enrollment is anticipated to begin by the end of this year. The Phase 1 trial will evaluate VCTX210's safety, tolerability, and immune evasion. This milestone marks a significant step in developing gene-edited stem cell therapies for diabetes.

CRISPR Therapeutics reported significant progress across its clinical portfolio in the third quarter of 2021. Target enrollment for CTX001 trials in beta thalassemia and sickle cell disease has been achieved, supporting regulatory submissions planned for late 2022. Positive results from the Phase 1 CARBON trial for CTX110 indicate promising efficacy for B-cell malignancies, with overall response rates demonstrating competitive profiles compared to existing therapies. However, the company reported a net loss of $127.2 million for the quarter, up from $92.4 million a year prior.

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two upcoming virtual investor conferences. The Credit Suisse 30th Annual Healthcare Conference is scheduled for November 8, 2021, at 1:00 p.m. ET, followed by the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-event. CRISPR Therapeutics specializes in gene editing using its CRISPR/Cas9 platform, addressing serious diseases through innovative therapeutics.

CRISPR Therapeutics (Nasdaq: CRSP) appointed Brendan Smith as Chief Financial Officer, effective immediately. Smith succeeds Michael Tomsicek, who is retiring after four years, and will assist in a smooth transition until the end of 2021. Smith brings over 20 years of experience, previously serving as CFO of Translate Bio, which was acquired by Sanofi for $3.2 billion. CEO Samarth Kulkarni highlighted Smith's expertise during a critical growth phase for CRISPR Therapeutics, which focuses on gene-based medicines for serious diseases using CRISPR/Cas9 technology.

CRISPR Therapeutics (CRSP) announced promising results from its Phase 1 CARBON trial, evaluating CTX110 for treating large B-cell lymphoma (LBCL). The trial reported a 58% overall response rate (ORR) and a 38% complete response (CR) rate in patients treated at Dose Level 2 and above, with durable responses noted over 18 months. The safety profile was favorable, showing no Grade 3 or higher cytokine release syndrome. CRISPR plans to expand the CARBON trial into a potentially registrational study in Q1 2022, supporting the development of CTX110 as an effective 'off-the-shelf' therapy.

CRISPR Therapeutics announced a virtual event scheduled for October 12, 2021, at 4:30 p.m. ET to discuss clinical data from its ongoing Phase 1 CARBON trial. This trial evaluates the safety and efficacy of CTX110, an investigational CAR-T therapy targeting CD19 for treating relapsed or refractory B-cell malignancies. Investors and stakeholders can join via a conference call or through a live webcast. CTX110 is a gene-edited allogeneic CAR-T therapy developed by CRISPR Therapeutics, focusing on significant diseases using their proprietary CRISPR/Cas9 technology.